多功能纳米材料干扰瘤微环境中的铁亡
Yurong Liu1, Yunheng Liu1, Xinting Li1
1School of Pharmacy, The Key Laboratory of Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine of China, Binzhou Medical University, Yantai, 264003, People's Republic of China.
International journal of nanomedicine
|March 3, 2025
概括
纳米材料通过调节铁亡,依赖于铁的细胞死亡途径,为癌症提供了有希望的治疗策略. 这种方法向瘤细胞,提高治疗疗效,减少副作用.
科学领域:
- 生物医学工程 生物医学工程
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 铁亡是一种编程细胞死亡途径,在癌症生物学中至关重要,由铁的积累和谷氨耗尽驱动.
- 瘤细胞的高铁需求创造了一个可用于诱导铁亡的漏洞.
- 纳米材料在癌症治疗中对调节铁化具有独特的优势.
研究的目的:
- 审查基于纳米材料的瘤细胞铁灭调节的最新进展.
- 评估当前的景观,新兴趋势和纳米材料在该领域的治疗应用.
- 探索纳米材料调节铁亡的机制,包括铁离子调节,谷胺活性和脂质过氧化.
主要方法:
- 关于铁和纳米材料在瘤学中的应用的当前研究的文献综述.
- 对针对癌细胞和诱导/抑制铁亡的纳米材料特性进行分析.
- 合成关于纳米材料对铁灭调节机制的信息.
主要成果:
- 纳米材料在向瘤细胞,提高药物疗效和最大限度地减少副作用方面显示出显著的潜力.
- 具体的策略包括调节铁离子稳态,干扰谷氨合成和脂质过氧化途径.
- 不同的纳米材料设计提供了量身定制的方法来诱导或抑制铁灭.
结论:
- 纳米材料通过精确控制ferroptosis,在癌症治疗方面具有相当大的治疗前景.
- 使用纳米材料对铁亡途径进行有针对性的调节,可能导致各种疾病的新型治疗策略.
- 预计将进一步开发基于纳米材料的铁灭诱导剂/抑制剂,以扩大治疗选择.
相关概念视频
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K


